Naturalendo Tech Valuation
Is A168330 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A168330 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate A168330's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A168330's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A168330?
Key metric: As A168330 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is A168330's PS Ratio? | |
|---|---|
| PS Ratio | 2.3x |
| Sales | ₩21.84b |
| Market Cap | ₩44.58b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2x |
| Enterprise Value/EBITDA | -19x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does A168330's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.2x | ||
A389030 GENINUS | 6.9x | n/a | ₩44.7b |
A036480 Daesung Microbiological Labs | 1.5x | n/a | ₩36.7b |
A086060 GeneBioTech Ltd | 0.4x | n/a | ₩29.8b |
A373110 Xcell Therapeutics | 28x | n/a | ₩52.3b |
A168330 Naturalendo Tech | 2.3x | n/a | ₩44.6b |
Price-To-Sales vs Peers: A168330 is good value based on its Price-To-Sales Ratio (2.3x) compared to the peer average (9.2x).
Price to Sales Ratio vs Industry
How does A168330's PS Ratio compare vs other companies in the KR Biotechs Industry?
| 26 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 8.7x | 38.6% | |
A168330 Naturalendo Tech | 2.3x | n/a | US$31.92m |
A006280 GC Biopharma | 1x | 9.0% | US$1.15b |
A096530 Seegene | 2.7x | 15.7% | US$765.97m |
| 26 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 8.7x | 81.6% | |
A168330 Naturalendo Tech | 2.3x | n/a | US$31.92m |
Price-To-Sales vs Industry: A168330 is good value based on its Price-To-Sales Ratio (2.3x) compared to the KR Biotechs industry average (8.7x).
Price to Sales Ratio vs Fair Ratio
What is A168330's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.3x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate A168330's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
JW Pharmaceutical
₩591.4b
Manufactures and sells medicines and medical supplies in Japan and internationally.
A001060
₩23,650.00
7D
-2.3%
1Y
-17.5%
Hugel
₩2.8t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩259,000.00
7D
-5.3%
1Y
67.2%
J2KBIO
₩54.3b
A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.
A420570
₩9,510.00
7D
2.7%
1Y
n/a